These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32810773)

  • 1. Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil.
    Lopes DG; Tamayo A; Schipp B; Siepmann T
    Thromb Res; 2020 Dec; 196():4-10. PubMed ID: 32810773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
    Gulati S; Eckman MH
    Ann Intern Med; 2023 Jan; 176(1):1-9. PubMed ID: 36571839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
    Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
    J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
    Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R; Kwong WJ; White RH; Goldhaber SZ
    Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Utility Analysis Comparing Direct Oral Anticoagulant and Low Molecular Weight Heparin Therapies for Secondary Prevention of Cancer-Associated Thrombosis.
    Shin YE; Kumar A; Hwang M; Mackey M; Wu WK
    Clin Drug Investig; 2022 Dec; 42(12):1075-1083. PubMed ID: 36315349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis.
    Kang W; Peng K; Yan VKC; Al-Badriyeh D; Lee SF; Yiu HHE; Wei Y; Li STH; Ye X; El Helali A; Lam KO; Lee VHF; Wong ICK; Chan EW
    J Pharm Policy Pract; 2024; 17(1):2375269. PubMed ID: 39027009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
    de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
    Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.
    Li A; Manohar PM; Garcia DA; Lyman GH; Steuten LM
    Thromb Res; 2019 Aug; 180():37-42. PubMed ID: 31200341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis.
    Connell NT; Abel GA; Connors JM
    Thromb Res; 2017 Feb; 150():53-58. PubMed ID: 28039844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
    Mahmoudi M; Sobieraj DM
    Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting.
    Wu Y; Zhang C; Gu ZC
    Front Cardiovasc Med; 2021; 8():675200. PubMed ID: 34268343
    [No Abstract]   [Full Text] [Related]  

  • 16. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
    Shah A; Shewale A; Hayes CJ; Martin BC
    Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
    Gould MK; Dembitzer AD; Sanders GD; Garber AM
    Ann Intern Med; 1999 May; 130(10):789-99. PubMed ID: 10366368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
    Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
    Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.